Digging deeper into GWAS signal using GRIN implicates additional genes contributing to suicidal behavior

Kyle A. Sullivan [1], Matthew Lane [2], Mikaela Cashman [1], J. Izaak Miller [1], Mirko Pavicic [1], Angelica M. Walker [2], Ashley Cliff [2], Jonathon Romero [2], Xuejun Qin [3,4], Jennifer Lindquist [3], Niamh Mullins [5,6], Anna Docherty [7], Hilary Coon [7,8], Douglas M. Ruderfer [9,10,11,12], International Suicide Genetics Consortium, VA Million Veteran Program, MVP Suicide Exemplar Workgroup, Michael R. Garvin [1], John P. Pestian [1,13], Allison E. Ashley-Koch [4,15], Jean C. Beckham [3,14,15], Benjamin McMahon [16], David W. Oslin [17,18], Nathan A. Kimbrel [*3,4,15,19], Daniel A. Jacobson [*1], and David Kainer [*1]

Affiliations:
[1] Computational and Predictive Biology, Oak Ridge National Laboratory, Oak Ridge, TN, USA
[2] The Bredesen Center for Interdisciplinary Research and Graduate Education, University of Tennessee Knoxville, Knoxville, TN, USA
[3] Durham Veterans Affairs Health Care System, Durham, NC, USA
[4] Duke University School of Medicine, Duke University, Durham, NC, USA
[5] Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
[6] Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
[7] Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, UT, USA
[8] Huntsman Mental Health Institute, University of Utah School of Medicine, Salt Lake City, UT, USA
[9] Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
[10] Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA
[11] Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA
[12] Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN, USA
[13] Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA
[14] Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
[15] VISN 6 Mid-Atlantic Mental Illness Research, Durham Veterans Affairs Health Care System, Durham, NC, USA
[16] Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, USA
[17] VISN 4 Mental Illness Research, Education, and Clinical Center, Center of Excellence, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA
[18] Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, PA, USA
[19] VA Health Services Research and Development Center of Innovation to Accelerate Discovery and Practice Transformation, Durham, NC
* Correspondence: kainerd@ornl.gov, jacobsonda@ornl.gov, nathan.kimbrel@va.gov

Abstract

Genome-wide association studies (GWAS) identify genetic variants underlying complex

traits but are limited by stringent genome-wide significance thresholds. Here we dramatically

relax GWAS stringency by orders of magnitude and apply GRIN (Gene set Refinement through

Interacting Networks), which increases confidence in the expanded gene set by retaining genes

strongly connected by biological networks from diverse lines of evidence. From multiple GWAS

summary statistics of suicide attempt, a complex psychiatric phenotype, GRIN identified

additional genes that replicated across independent cohorts and retained genes that were more

biologically interrelated despite a relaxed significance threshold. We present a conceptual model

of how these retained genes interact through neurobiological pathways to influence suicidal

behavior and identify existing drugs associated with these pathways that would not have been

identified under traditional GWAS thresholds. We demonstrate that GRIN is a useful community

resource for improving the signal to noise ratio of GWAS results.

Introduction

Genome-wide association studies (GWAS) can identify the genetic basis of complex

phenotypes but interpreting the results of these studies is often challenging. SNP-level results

from GWAS often need gene assignment for understanding downstream functions, but SNP-to-

gene assignment is challenging for intergenic SNPs[1–4]. Moreover, while the resulting gene set

may contain genes that affect the phenotype, these "true positive" genes are often interspersed

with false positives as a consequence of confounding experimental factors and incorrect SNP-to-

gene assignments. False positive genes can mislead efforts to understand the genetic architecture

of a trait, so it is important that they are filtered out. This becomes even more crucial for GWAS

that produce few associated genes at traditional genome-wide significance (i.e., $p < 5e^{-8}$). For

these cases it is often necessary to investigate SNPs at less stringent p-value thresholds to find

relevant loci, at the risk of introducing false positives.

Polygenic traits are typically influenced by genes from multiple pathways working in

concert with each other within the broader biological system[5]. Given enough information from

diverse experimental sources, it should be possible to find functional lines of biological evidence

connecting any pair of truly causal genes to each other more strongly than pairs of random genes.

When considered as a set (*e.g.*, from a GWAS or differential gene expression), the true positive

causal genes are very likely to be functionally connected to one another. Conversely, false

positive genes from a GWAS will likely be random and therefore far less functionally connected

to the other genes in the set. Given a gene set, one could conceivably determine which genes are

most likely to be false positives if the gene set can be parsed effectively by including thorough

gene interaction information.

To solve this important biological problem, we present GRIN – Gene set Refinement

through Interacting Networks – an approach that removes biologically disparate, false positive

genes in a gene set based upon biological network topology. GRIN uses a network representation

of system-wide gene-to-gene interactions from diverse experimental sources. Starting from a

user-defined gene set, GRIN explores the network topology to determine how strongly these

genes are interconnected. Next, GRIN compares the connectivity among these genes to the

connectivity found among random genes to determine which of the user's genes are likely to be

false positives. We validated GRIN by testing its ability to separate well-characterized,

functionally related "gold standard" genes from random genes using a large multiplex network[6].

We then applied GRIN to suicide attempt GWAS summary statistics, a complex

psychiatric phenotype. Even though heritability estimates range from 17-55%[7,8], this psychiatric

disorder has elicited few genome-wide significant variants to date[8–11]. We analyzed independent

suicide attempt GWAS results from the Million Veteran Program (MVP[11]) and the International

Suicide Genetics Consortium (ISGC[9]). As few variants were significant at traditional genome-

wide significance, we explored SNPs at a less stringent threshold and used multiple SNP-to-gene

assignment methods to elucidate the underlying mechanisms of the heritable components of

suicidality. GRIN identified genes with higher probability of contributing to suicide attempt

pathophysiology, reducing false positive genes. Thus, we demonstrate GRIN's utility in

identifying key biological mechanisms from GWAS signals, and subsequently identify putative

drug targets for future suicide prevention studies.

Results

GRIN workflow.

A summary of the GRIN workflow is presented in **Figure 1**. GRIN inputs include a gene

set and a previously generated multiplex network. In Stage 1, all experimentally-derived (*e.g.*,

GWAS) "seed" genes are ranked based upon biological network connectivity. GRIN also

performs this task on random gene sets of equivalent size to produce an empirical null rank

distribution. In Stage 2, a sliding window is used to compare the ordered ranks of

experimentally-derived genes to the equivalent ordered ranks within the null distribution using

the Mann-Whitney U test, and the *p*-value of the Mann-Whitney U test is plotted for each

window to form a curve. The elbow of this curve indicates the cutoff point at which the ranks are

equivalent between the seed gene set and the null distribution (indicating low functional

interrelatedness), and genes following this cutoff point are filtered out.

GRIN accurately removes false positive genes as determined by benchmarking with biologically interrelated, "gold standard" gene sets.

We first tested GRIN on 30 biologically-interrelated, "gold standard" gene sets mixed

with an equivalent amount of randomly drawn genes (1:1 ratio), and repeated this 100 times per

gold standard gene set (**Fig. 2A, Supplementary Table 1**). GRIN Stage 1 ranked gold standard

genes more highly than most random genes in any given test set, achieving median area under

the receiver operating characteristic curve (AUROC) and median area under the precision-recall

curve (AUPRC) values of 0.950 ± 0.059 and 0.896 ± 0.084 respectively across the 30 gold

standard gene sets (**Fig. 2B-C**). This indicated highly accurate gene ranking in GRIN Stage 1,

which is necessary for successful outcomes at Stage 2. GRIN Stage 2 effectively classified true

and false positive genes at the cutoff point (median precision 0.810 ± 0.134; recall $0.914 \pm$

0.167; specificity 0.880 ± 0.197; **Fig. 2D, Supplementary Fig. 1**). On average, 46.0% of the

gene set was discarded as noise (0.460 ± 0.143), and less than 9% of true positive gold genes

were discarded (median recall 0.914).

Next, we tested GRIN's ability to refine gene sets containing varying proportions of

random genes. When gold standard genes outnumbered random genes by 2:1, precision ($0.967 \pm$

0.060), recall (0.735 ± 0.331), and specificity (0.971 ± 0.088) were consistently high compared

to expected values from random classification (precision = 0.66, specificity = 0.66). Precision,

recall, and specificity values decreased as the ratio of gold genes to random genes in the gene

sets decreased (1:1, 1:2, 1:4) but were consistently better than random chance (**Fig. 2E,**

Supplementary Fig. 2).

Finally, we tested whether GRIN could retain multiple distinct functional groups when

mixed with random genes. This test case is important since a real-world gene set for a complex

trait is likely to contain multiple functional groups. When given gene sets with two distinctive

biological functions ("dopaminergic synaptic signaling" and "myelination") at 1:1 or 2:1 ratios

of gold standard genes to random genes, GRIN generated much better precision and specificity

compared to random chance while retaining high values for recall (2:1 merged gold

standard:random – precision: 0.931 ± 0.042, recall: 0.742 ± 0.141, specificity: 0.891 ± 0.094;

1:1 merged gold standard:random – precision: 0.789 ± 0.103, recall: 0.930 ± 0.116, specificity:

0.767 ± 0.174; **Fig. 2F**).

GRIN retains biologically interrelated genes from the Million Veteran Program (MVP)

suicide attempt GWAS at less stringent significance thresholds.

After benchmarking GRIN on gold standard gene sets, we applied it to suicide attempt

GWAS summary statistics from the Million Veteran Program (MVP[11]) to understand which

genes contribute to psychiatric pathophysiology in this military veteran population. We utilized

both conventional MAGMA[4] and H-MAGMA[1] solely for gene assignment from SNPs at

different genome-wide significance thresholds (**Fig. 3A**). Only five SNPs were significant below

the traditional threshold of genome-wide significance ($p < 5e^{-8}$) which were assigned to three

total genes (*SPATA17, TSHZ2,* and *ENSG00000227705*; **Supplementary Tables 2 and 3**). In

order to explore additional genes contributing to suicide attempt pathophysiology, we explored

markedly less stringent *p*-value thresholds which expanded the GWAS-derived gene sets. We

only examined SNPs and resulting genes at the $p < 1e^{-5}$ threshold since the numbers of genes

obtained at less stringent thresholds became unwieldy to interpret in a unified context

(**Supplementary Table 2**).

MVP SNPs were assigned to 122 genes at $p < 1e^{-5}$ (**Supplementary Tables 2 and 4**). We

applied GRIN to this gene set in order to limit the higher number of potential false positive genes

introduced at this threshold. GRIN retained 65 genes and removed 57 genes from the gene set

(**Fig. 3B-C, Supplementary Table 5**). Next, to determine if GRIN successfully retained

biologically interrelated genes we used ToppGene[12] to compare a variety of gene set enrichments

(**Methods**) of MVP genes before and after GRIN. The 122 unfiltered genes were not

significantly enriched for any GO terms but were enriched for 203 combined drug and disease

enrichments, including "substance dependence" (DisGeNET C0038580; **Supplementary Table**

6). Intriguingly, after refining the gene set with GRIN, 1449 enrichments were significant from

65 retained genes, including 18 transcription factor binding sites and five GO molecular function

enrichments (*e.g.*, "adenyl ribonucleotide binding," **Supplementary Table 7**). Conversely,

GRIN removed 57 genes that manifested no significant enrichments. Thus, filtering MVP genes

at a far less stringent GWAS significance threshold with GRIN resulted in a more functionally

enriched gene set by improving the signal-to-noise ratio.

GRIN retains biologically interrelated genes from multiple International Suicide Genetics

Consortium (ISGC) GWAS at a less stringent significance threshold.

We sought to identify which genes retained by GRIN from MVP were replicated in two

independent, civilian suicide attempt GWAS compiled by the International Suicide Genetics

Consortium (ISGC[9]). This study contained summary statistics from: 1) a European ancestry

GWAS of suicide attempt in civilians (SA-EUR) and 2) a GWAS of the SA-EUR population

conditioned by major depressive disorder (MDD) diagnosis status (SA-MDD). At a threshold of

$p < 5e^{-8}$, only seven SA-EUR genes and three SA-MDD genes were significantly associated

(**Supplementary Tables 2-3**).

We then applied the same, less stringent significance threshold ($p < 1e^{-5}$) to identify

additional genes, and applied GRIN to remove potential false positives. Following SNP-to-gene

assignment, 252 genes were identified from SA-EUR and 62 genes were identified from SA-

MDD (**Supplementary Tables 2 and 4**). Prior to GRIN, 25 genes were common to both SA-

EUR and SA-MDD (**Fig. 4**). Following GRIN, 11 genes were commonly retained from both sets

of summary statistics, 8 genes were commonly removed, and 6 genes were removed or retained

from one set only (**Fig. 4; Supplementary Tables 8-9**). Next, we compared ToppGene gene set

enrichments before and after GRIN to investigate if GRIN functionally refined these gene sets.

At $p < 1e^{-5}$, 243 enrichments were significant from the unfiltered SA-EUR gene set, including 33

transcription factor binding sites and 114 GO enrichments (**Supplementary Table 10**). GRIN

retained highly interrelated genes from SA-EUR as demonstrated by 274 significant enrichments,

including 132 significantly enriched GO terms and 44 transcription factor binding sites

(**Supplementary Table 11**). Conversely, only two enrichments were obtained from removed

SA-EUR genes, indicating little functional interrelatedness among these genes (**Supplementary**

Table 12). Similarly, 65 enrichments were identified from SA-MDD before GRIN while 247

enrichments were identified in the GRIN retained gene set, including an enrichment for

"schizophrenia," a mental health disorder which presents an increased risk of suicidality

(DisGeNET C0036341; **Supplementary Tables 13-14**). Conversely, only 31 enrichments were

identified in the removed gene set (**Supplementary Table 15**). This strongly indicated that

GRIN-filtered SA-EUR and SA-MDD gene sets contained highly interrelated genes that were

relevant to neurobiological pathways.

GRIN retains a majority of genes from the union of the MVP and ISGC summary

statistics, enhancing functional gene set enrichment.

162   In a process similar to a meta-analysis, we applied GRIN to the union of MVP and ISGC

genes to identify replicated genes across cohorts and identify unified biological mechanisms.

Prior to applying GRIN, at $p < 1e^{-5}$ one gene (*PDE4B*) was common among all results, three

genes were common to only MVP and SA-EUR, and 24 genes were common to only SA-EUR

and SA-MDD (**Fig. 5**). After applying GRIN to the union of all genes, 17 genes common to

multiple summary statistics were retained (over 50%), including *PDE4B*, 2 out of 3 common

genes between MVP and SA-EUR, and 14 out of 24 common genes between SA-EUR and SA-

MDD (**Fig. 5, Supplementary Table 16**). Conversely, 8 genes between SA-EUR and SA-MDD

and 1 gene between MVP and SA-EUR were commonly removed at this threshold (**Fig. 5,**

Supplementary Table 16).

172   Next, we assessed GRIN's ability to improve gene set enrichment analysis using genes

common to two or more sets of summary statistics. Prior to GRIN there were 1324 significant

enrichments from the 28 genes common to multiple data sets (**Fig. 6**, **Supplementary Tables**

16-17). Intriguingly, 1443 significant enrichments were obtained from the 17 genes commonly

retained by GRIN in multiple data sets, including 126 GO terms such as "dopaminergic synapse"

(**Fig. 6**, **Supplementary Table 18**). Conversely, only 358 enrichments were significant from the

11 intersecting genes removed by GRIN, indicating lower interrelatedness among these genes

compared to the retained set (**Supplementary Table 19**). In addition to introducing newly

enriched terms, GRIN improved the significance of the majority of enriched terms from the pre-

filtered gene set. Of the 1324 enrichments obtained from the unfiltered set of genes common to

multiple suicide attempt summary statistics, 1259 of these enrichments were retained; 1168 of

these retained enrichments were more significant following GRIN, strongly indicating that

retained genes constituted a more biologically cohesive set (**Fig. 6, Supplementary Tables 18-**

19).

Similarly, when applying GRIN to each set of summary statistics separately, 13

intersecting genes were commonly retained and 9 intersecting genes were commonly removed

(**Supplementary Fig. 3**, **Supplementary Table 20**). This resulted in more numerous and

statistically significant gene set enrichments using intersecting GRIN-retained genes compared to

the unfiltered gene set or GRIN-removed genes (**Supplementary Fig. 4**, **Supplementary Tables**

21-22).

Retained genes from GRIN identify putative pathophysiological pathways involved in

suicide attempt, leading to drug repurposing/side effect candidates.

Using genes retained by GRIN, we identified biological pathways implicated by suicide

attempt GWAS (**Fig. 7**). Only one of the three genes identified from MVP GWAS at $p < 5e^{-8}$

(*TSHZ2*) was retained by GRIN at $p < 1e^{-5}$. Multiple genes identified in both cohorts were

relevant to dopaminergic signaling, including the dopamine D2 receptor subunit (*DRD2*) and

phosphodiesterase 4-beta (*PDE4B*) as well as a protein kinase A subunit (*PRKAR2A*) from MVP,

which can subsequently modulate cAMP/CREB-mediated transcription of genes important for

synaptic plasticity[13]. Additionally, *SGIP1* was retained by GRIN in MVP and SA-EUR summary

statistics, which affects presynaptic vesicle release and emotional state[14,15]. Furthermore, genes

involved in neurotransmitter release (*BRSK1*) and glutamatergic synapses (*CELSR3*[16]) were

identified along with *ICE2*, which is induced by NMDA receptor activity[17,18]. *NCAM1* was also

retained by GRIN, which is a crucial mediator of synaptic plasticity and memory processes[19,20].

Multiple genes involved in cytoskeletal reorganization were also identified including

CDC42BPB, *MAP4*, and *MARK3*. Moreover, *TSHZ2*, *SMARCC1*, and *ZNF589* were retained by

GRIN and have been implicated in neurodevelopmental processes while *RCOR1* is important for

neural progenitor differentiation into neuronal and glial subtypes[13,21–24]. Finally, a number of

genes involved in global translation processes were identified (*DALRD3*, *DHX30*, and *EIF5*),

two of which have been previously implicated in neurodevelopmental disorders arising from

missense variants[25,26] (**Fig. 7**).

Finally, we identified drugs that may modulate suicidal behavior based on GWAS-

implicated genes retained by GRIN. Multiple drugs target the dopamine D2 receptor subunit,

including the FDA-approved drugs clozapine (used to prevent suicidal behavior in

schizoaffective individuals[27]) and amisulpride (**Fig. 8, Supplementary Table 23**). Roflumilast

and a number of other molecular compounds also directly affect *PDE4B*. Furthermore,

fostamatinib is known to affect 8 genes implicated in both MVP and SA-EUR suicide attempt

GWAS. These drug-gene target links warrant future studies to ensure that they do not present

increased risk for suicidality as a side effect, and to evaluate candidates for drug repurposing for

suicide prevention.

Discussion

Here we introduced GRIN, a workflow based on networks of biological relationships to

enable the relaxing of GWAS thresholds while reducing the impact of false positives, thus

producing an expanded prioritized gene set compared to a GWAS using the standard significance

threshold. Genome-wide association studies are subject to statistical challenges that have

historically made it difficult to identify a large proportion of trait-relevant genes. In human

studies, genes that may contribute to disease have traditionally been identified from SNP

associations at a genome-wide significance threshold of $p < 5e^{-8}$, but for many traits GWAS

often fails to find a comprehensive signal at this stringent threshold, especially complex traits

controlled by many small-effect loci. Yet we know that much of the signal of heritability lies

below this threshold. Relaxing the stringency gives access to more SNPs (and hence more genes)

that may be associated with the trait, at the risk of introducing an increasing proportion of false

positives that will confound downstream analyses. GRIN operates on the concept that genes

affecting the same trait are likely to have some sort of functional relationship, even if based upon

minor and/or indirect effects. Given a set of genes from a GWAS, true positive genes should

therefore be functionally related to each other in some way, while false positive genes will be

functionally distant with respect to each other and with respect to the true positive genes. We

demonstrated that GRIN accurately partitions an input gene set into two subsets based on this

mechanism and used it to boost GWAS signals. In contrast to other network-based propagation

tools for enhancing GWAS (*e.g.,* NAGA[28], uKIN[29], GWAB[30]), GRIN simultaneously enhances

GWAS sensitivity while reducing the risk of false positive genes from being included.

The first stage of GRIN requires a representation of known relationships between all

genes in a network format. Here we used a biological multiplex network which captures a wide

variety of relationship types across its 10 layers. One could instead use a pre-existing network

based on the species of interest, such as HumanNet[31], YeastNet[32], or AraNet[33]. However,

GRIN's capacity to accurately refine gene sets is limited by the connectivity represented in the

network. A poor network lacking sufficient biological relationships would result in reduced

ability to distinguish between functionally related genes and random noise. We therefore

included various experimental data sources and generated a frontal cortex-specific predictive

gene expression network using an explainable-AI methodology (iRF-LOOP[34]), which can define

relationships that were not present in the literature. This novel, tissue-specific weighted network

is a powerful community resource, as iRF-LOOP-derived networks can contain more informative

relationships compared to traditional gene co-expression networks by an order of magnitude[34].

Determining the functional relatedness between the genes in a GWAS gene set can be

performed by many algorithms that operate on a biological network. Network propagation

algorithms use information encoded in the topology of each layer simultaneously, providing a

systems-level view of gene-to-gene relationships. Utilizing one such algorithm (random walk

with restart, RWR), we achieved high AUROC, AUPRC, precision, recall, and specificity.

Future studies are warranted to explore which sources of experimental data (*e.g.*, protein-protein

interaction, transcription factor binding) are most influential for retaining biologically

interrelated genes with GRIN.

We demonstrated that GRIN works with simulated noisy gene sets similar to what is

obtained from a GWAS or differential gene expression experiment. GRIN successfully

partitioned curated gene sets spiked with random genes into signal and noise subsets, even when

given multiple functional groups or a high noise ratio. The results confirm that RWR indeed

ranks the functional group(s) of genes highly while random genes mostly receive poor rankings.

When applied to real-world data, it is up to GRIN's second stage to determine the optimal cutoff

point that divides functional genes from false positive genes. The strong simulated test results

provide confidence that when GRIN is applied to GWAS results, the true positive genes should

rise to the top of the rankings as long as they are more functionally related to each other than

random genes are, thus providing a retained set that has a higher signal-to-noise ratio than if

GRIN was not used at all.

After applying GRIN to expanded GWAS results at $p < 1e^{-5}$, we obtained more gene set

enrichments in the retained set with consistently higher levels of significance, despite this set

being considerably smaller. Thus, GRIN removed false positives that were diluting the functional

signal in the original gene set. The fact that the removed gene set was scarcely enriched supports

this argument. By separating a gene list into retained and removed subsets, the user can identify

additional biologically relevant pathways that may be missed by enrichment analyses on the

whole set alone due to dilution with noise.

While we demonstrated that GRIN achieves high accuracy using gold standard gene sets,

GRIN sometimes discarded true positive genes. This indicates that not all genes removed by

GRIN are necessarily irrelevant to the trait or disease, and the removed set should be considered

but with lower confidence than the retained set. It is also important to consider the possibility for

false positives and false negatives to be re-classified as new experimental data sources become

available. For example, some genes removed by GRIN currently have few experimental gene-

gene network relationships (*e.g.*, the non-coding RNA *RP11-839D17.3* and pseudogene

MRPS21P1). However, future experiments may identify their capacity to modulate

transcriptional or post-transcriptional processes with pathophysiological implications. Therefore,

GRIN output should be considered as guidance rather than a definitive determination of what is a

true or false positive.

Combined with multiple SNP-to-gene assignments, incorporating SNPs at a less stringent

significance threshold and applying GRIN elucidated additional suicide-associated genes and

pathways. In addition to conventional MAGMA, we leveraged frontal cortex-specific chromatin

accessibility and H-MAGMA which refined SNP-to-gene assignment. While certain variants

have been previously described (*e.g.*, variants in *DRD2*, *PDE4B*, and *SPATA17*[8,9,11]), the present

study characterizes additional genes contributing to dendritic structure and multiple key

neurotransmitter pathways associated with suicidality. Among these additional genes, missense

variants in *CDC42BPB*[35], *DALRD3*[26], *DHX30*[25], *SMARCC1*[22], and *ZNF589*[36] are known to

impair behavioral and neurodevelopmental processes. While the genetic variants in the present

study did not include these missense or loss-of function variants, it is possible that the variants

implicated in the present suicide attempt summary statistics may alter the transcription of these

genes. For example, the retained gene sets were enriched for multiple transcription factor binding

sites, including an NFAT transcription factor binding site enrichment common to each GWAS

based on different genes (TGGAAA, TRANSFAC NFAT_Q4_01; **Supplementary Tables 7,**

11, and 14). Variants leading to differential gene transcription may have downstream

developmental or behavioral consequences leading to increased impulsivity and ultimately an

increased risk of suicidality. In addition, multiple genes were implicated in cytoskeletal

reorganization. *CDC42BPB* encodes MRCKbeta, a protein kinase that is induced by long-term

potentiation in rodent models and mediates dendritic spinogenesis by actin-myosin filament

phosphorylation[37,38]. *MAP4* is a microtubule-associated protein (MAP) and *MARK3* has been

shown to phosphorylate tau (*MAPT*), another MAP which accumulates in multiple

neurodegenerative disorders[39,40]. Moreover, *RCOR1* is a subunit of the REST/CoREST complex

and has been shown to affect *CELSR3* and *SMARCC1* transcription in mouse models[16,22], and

SMARCC1 has been implicated in autism as a core component of the SWI/SNF complex[23,41].

These findings point to the possible pleiotropic nature of these genes being associated with

multiple neurological disorders.

By lowering the significance threshold and applying GRIN to refine suicide GWAS gene

sets, we identified previously characterized drug targets (*DRD2*, *MARK3*, and *PDE4B*) and drug

repurposing/side effect candidates that would not have been detected otherwise. Notably, the

DRD2 antagonist clozapine is the only FDA-approved drug with on-label use to prevent suicidal

behavior[27]. Amisulpride is also a *DRD2* antagonist that has been shown to exhibit antipsychotic

and antidepressant activities[42]. Intriguingly, fostamatinib targets 8 genes implicated by suicide

attempt GWAS including *MARK3* and *PDE5B*, a different phosphodiesterase than the *PDE4B*

gene implicated in suicide attempt GWAS[43]. Moreover, it is important to understand if drugs can

present adverse side effects modulating suicidal behavior. For example, the *PDE4B* inhibitor

roflumilast has a rare adverse side effect of increased suicidality in some individuals[44]. Further

studies are warranted to understand how pharmacological manipulation of these GWAS-

implicated drug targets affect the propensity of suicidal behaviors in at-risk individuals.

GRIN is a powerful tool for identifying biologically interrelated genes and for identifying

true positive variants and associated genes from GWAS. In effect, GRIN synthesizes multiple

lines of evidence to determine which genes should be investigated further, automating a task that

researchers usually do manually post-GWAS. By applying this tool to multiple GWAS results,

we identify new genes involved in suicide pathophysiology that may lead to important clinical

insights.

Acknowledgements and Disclosures

This research used resources of the Oak Ridge Leadership Computing Facility at the Oak Ridge

National Laboratory, which is supported by the Office of Science of the U.S. Department of

Energy under Contract No. DE-AC05-00OR22725. GWAS summary statistics from the Million

Veteran Program used in this study will be made available on the NIH database of Genotypes

and Phenotypes (dbGaP) under accession ID phs001672.v1.p. Summary statistics from the

International Suicide Genetics Consortium are available at https://tinyurl.com/ISGC2021. The

authors declare no competing interests.

Funding Sources

This work was sponsored by MVP CHAMPION (DAJ), NIH grants DA041913 (DAJ),

DA051908 (DAJ), MH116269 (DMR), MH121455 (DMR), Brain & Behavior Research

Foundation (NARSAD Young Investigator Award No. 29551 [NM]), Department of Veterans

Affairs (VA) Clinical Science Research and Development (CSR&D) grants lK6BX003777 (JCB,

NAK, DWO) and lK6BX003777 (JCB), and the VA Million Veteran Program (MVP). This

publication does not represent the views of the VA or the United States Government. We also

thank and acknowledge MVP (Office of Research and Development, Veterans Health

Administration), the MVP Suicide Exemplar Workgroup, and the ISGC for their contributions to

this manuscript. A complete listing of contributors from the MVP, MVP Suicide Exemplar

Workgroup, and ISGC is provided in the Supplementary Materials.

Author Contributions

Conceptualization: KAS, DK, DAJ; Methodology: KAS, DK, DAJ; Software: KAS, ML, MCM, JIM, AC, JR, DK; Formal analysis: KAS, DK; Investigation: KAS, DK, XQ, JL, NM, DAJ; Resources: DR, XQ, DAJ; Writing - Original Draft: KAS, DK; Writing - Review & Editing: KAS, ML, MP, AMW, NM, AD, HC, DMR, MRG, AEAK, JCB, BM, DWO, NAK, DK, DAJ; Visualization: KAS, DK; Supervision: NAK, DAJ, DK; Project administration: AD, HC, DMR, JPP, AEAK, JCB, BM, DWO, NAK, DAJ; Funding acquisition: DMR, DK, DAJ.

Online Methods

Multiplex biological network generation.

In order to capture biological relationships from diverse types of biological evidence, a multiplex network was assembled from weighted network connections (edges) from a combination of publicly available and newly generated monoplex (single layer) networks. A multiplex network has an advantage over aggregate multilayer networks in that the unique topology of each layer is maintained, resulting in generally higher functional predictive ability[45]. Multiple component networks from HumanNet v2[31] were used (co-functional links by co-citation, co-essentiality[46], co-expression, molecular pathway databases, gene neighborhood, phylogenetic profile associations, and orthologous protein-protein interactions transferred from model organisms [CC, CE, CX, DB, GN, PG, IL]), and a protein-protein interaction (PPI) network was generated by merging the following networks into a single monoplex layer: HumanNet v2 component PPI networks (HT, LC), and high-confidence physical protein-protein interactions from STRING version 11.0[47] (taxa = 9606, protein.actions.v11.0, mode=binding, min score = 700). A transcription factor-gene network layer was included based on a previously published, human brain-specific transcription factor binding site network[48]. Newly generated Predictive Expression Networks (PENs) were obtained using the Iterative Random Forest -

Leave One Out Prediction (iRF-LOOP) method[34,49] using individual-level RNA-seq expression

data from the Genotype-Tissue Expression (GTEx) project[50] from the frontal cortex (Brodmann

area 9). The resulting multiplex network was built using RWRtoolkit

(https://github.com/dkainer/RWRtoolkit), which incorporates command-line scripts and an R

library for generating multiplex networks and running the network exploration algorithm random

walk with restart (RWR) by building upon the RandomWalkRestartMH R package[45]. The

multiplex network used for all analyses comprises 10 layers, 51,183 unique genes, and 3,419,975

edges using $\delta = 0.5$, where δ is the probability of the random walker remaining in the current

network layer or moving to a different layer. The multiplex network used for all analyses is

publicly available at

https://github.com/sullivanka/GRIN/tree/main/test/suicide_weighted_Multiplex_0.5Delta.RData.

GRIN process.

GRIN leverages the hypothesis that false positive genes in gene sets are likely to be

functionally random with respect to the rest of the gene set, while true positive genes are likely to

share function with other members of the gene set. Using this theory, GRIN partitions a gene set,

such as from differential gene expression analysis or SNP-to-gene assignment from GWAS, into

retained and removed genes in a two-stage process.

In Stage 1, every gene in the network is ranked according to how connected it is to the

genes in the user-specified gene set (*e.g.*, GWAS-derived genes). This includes ranking the user-

specified genes themselves by using leave-one-out cross-validation (LOOCV). GRIN can make

use of any network exploration algorithm that can provide gene rankings. We chose RWR for its

robustness, but other propagation methods (*e.g.*, PageRank, heat diffusion) can also achieve

this[28,29,51]. RWR provides each gene with a rank that is a proxy for how easily each gene in the

network can be reached from the starting set of GWAS genes, including a rank for the GWAS

genes themselves. Genes with many paths and interactions to one or more of the GWAS genes

rank strongly, while genes that are isolated or distant from the GWAS genes rank poorly. In the

current implementation, this RWR-based ranking occurs based on network propagation of

probabilities of visiting a given gene in the multiplex network, which is based on a matrix

representation of the edge weights between genes in the multiplex network (i.e., the supra-

adjacency matrix composed of all intra- and inter-layer connections). Random walks are then

simulated many times by propagating the probability of the random walker exploring a given

gene beginning from the seed genes, and this process continues until the combined network

probabilities no longer change between simulated random walks by a given threshold ($1e^{-10}$),

thereby achieving convergence based upon an asymptotic number of simulated random walks.

The advantage of using a propagation algorithm like RWR is that genes that are not direct

neighbors of GWAS genes may still rank highly due to indirect paths. Additional parameters can

be used to tune RWR to favor certain network layers (τ) or adjust the probability of restart (r) at

seed genes. In all analyses in the present study, we used $r = 0.7$, equivalent τ values for all

network layers, and a multiplex network with $\delta = 0.5$ based on previous work that achieved good

performance using these parameters[45].

To obtain accurate rankings for each gene in a gene set of size n, we chose to implement

random walk with restart leave-one-out cross validation (RWR-LOOCV) n times, where in each

run one gene is left out and the other $n-1$ genes are used as seed genes (starting points) for the

random walker in the multiplex network. Each run of RWR-LOOCV generates a ranking of

every non-seed gene in the multiplex, including the left-out gene from the original seed gene set,

426 so that each gene in the user's obtains *n-1* rank values after *n* runs. Stage 1 then orders the genes

427 in the set from best to worst according to their median rank values. GRIN also needs a

428 representation of what Stage 1 results should look like for purely random gene sets of size *n*.

429 This empirical null distribution is generated by running RWR-LOO for 100 gene sets, each

430 containing *n* randomly sampled genes from the multiplex. The median rank at each position in

431 the order from 1 to *n* thus represents the empirical null distribution of ranks for this specific

432 multiplex and gene set size.

433   In Stage 2, a cutoff *C* between 1 and *n* is determined below which all gene set members

434 are considered the equivalent of random and can be discarded. A two-sided Mann-Whitney U

435 test from the R stats base package ("wilcox.test") is performed over a sliding window of size

436 $winsize = 0.15 \times n$ to see if the RWR-LOOCV ranks for the gene set members come from the

437 same distribution as the null distribution RWR-LOOCV ranks. The expectation is that a gene set

438 window containing functional groups of genes will have a very different ranking distribution to

439 the random genes in the equivalent null window, resulting in very small (significant) *p*-values.

440 On the other hand, if the window contains genes with little functional relatedness, the ranking

441 distribution will appear to be drawn from the null distribution and the *p*-value tends towards 1.

442 This test is run for each window sliding by 1, producing a *p*-value vector of length *n-winsize*.

443 The cutoff *C* is chosen by finding an elbow in the *p*-values using the open source R package

444 "Knee Arrower" with the method = "first" parameter set

445 (https://github.com/agentlans/KneeArrower). The output is a *retained* gene set and a *removed*

446 gene set.

Validation of GRIN using well-characterized gene sets.

To determine the ability of GRIN to effectively remove noise genes from a gene set, we obtained a variety of well-characterized ("gold") biologically interrelated gene sets and spiked them with random genes drawn from the full multiplex network. Given our application of this method to suicide GWAS summary statistics, we chose 20 gene sets related to diverse brain functions. We included an additional 10 gene sets related to other organ systems (lung and kidney) in order to demonstrate that GRIN could be adapted to other biological contexts. These thirty "gold standard" gene sets of functionally interrelated genes (see **Supplementary Table 1**), ranging in size from 10 to 225 genes, were derived from the following sources: Gene Ontology (GO[52]); Online Mendelian Inheritance in Man (OMIM[53]); and DisGENET[54]. Random genes were inserted into each gold set to create gene sets with a 1:1 signal-to-noise ratio (i.e. $N_{gold} : N_{random}$). For each of the 30 gold sets we generated 100 test gene sets using varying samples of random genes. GRIN was then used to filter out random genes from each test gene set and the effectiveness of the filter was evaluated using receiver operator characteristics (ROC) and precision/recall (PR) measured at every possible cutoff point, C, in each rank-ordered gene set.

For evaluation purposes, "true positive" genes were labeled as genes belonging to a gold gene set that were correctly retained by GRIN; "true negative" genes were randomly added genes that were correctly removed by GRIN; "false positive" genes were randomly added genes that were incorrectly retained by GRIN; and "false negative" genes were gold genes that were incorrectly removed by GRIN. ROC (false positive rate vs true positive rate), and PR curves (precision vs recall) were generated and area under ROC (AUROC) and area under PRC (AUPRC) values were calculated for each test gene set. Median AUROC and AUPRC were calculated for each of the 30 gold standard gene sets to indicate whether Stage 1 of GRIN ranked

gold genes more highly than random genes in general. After estimating the optimal cutoff C at

Stage 2, precision, recall, and specificity (true negatives / true negatives + false positives) were

calculated for the genes removed and the genes retained by Stage 2. Median precision, recall, and

specificity values were calculated across the 100 test gene sets for each of the 30 gold standard

gene sets. Values are presented as median +/- interquartile range (IQR).

GRIN was also tested on unequal ratios of gold standard genes and random genes using

the dopaminergic synaptic signaling gene set from GO (GO:0001963) and Acute Kidney Failure

gene set from DisGeNET (C0022660) – 2:1 gold genes to random genes, 1:2 gold genes to

random genes, and 1:4 gold genes to random genes. For each ratio of gold standard genes to

noise, 100 test sets were generated. Notably as precision increases (reduction of false positives),

there is a compensatory decrease in recall, as there is the possibility of throwing out too many

true positives, leading to an increased number of false negatives. Since there is a higher precision

value at lower noise levels, there is an inverse trend of decreasing recall at lower noise levels.

Finally, to test whether GRIN could remove random genes from gene sets containing

multiple groups belonging to biological processes that were functionally distinct, multiple gold

gene sets were combined and random noise also added. Dopaminergic synaptic transmission

(GO:0001963; 23 genes) and central nervous system myelination (GO:0022010; 20 genes) were

mixed with two ratios of random to gold standard genes – 2:1 gold genes:noise and 1:1 gold

genes:noise. This process was repeated to generate 100 gene sets of gold standard and random

genes for each ratio examined.

492 Million Veteran Program (MVP) suicide attempt genome wide association study (GWAS)

493 summary statistics.

Suicide attempts were identified from United States veterans as described previously[11].

Suicide attempts were characterized by using a combination of Veterans Healthcare

Administration (VHA) databases from the VA: the Suicide Prevention Application Network

(SPAN) database, electronic health record (EHR) information from the VA Corporate Data

Warehouse (CDW), and the CDW Mental Health Domain survey. For the MVP diagnosis,

suicide attempt was determined by the presence of one or more of the following International

Statistical Classification of Diseases and Related Health Problems (ICD)-9 and ICD-10

diagnostic codes in a subject's EHR: ICD-9: E950-959; ICD-10: T14.91, X60-62, X64, X66-

X83, Y87.0, Z91.5. Control patients were obtained from veterans enrolled in MVP without a

history of suicide attempt or suicidal ideation as determined by a combination of SPAN survey,

Mental Health Domain survey, and ICD diagnostic codes in the CDW database (suicidal ideation

codes: ICD-9: V62.84; ICD-10: R45.851). A total of 410,464 controls from various ancestries

(African, Asian, European, and Hispanic) were included for genome-wide association along with

14,535 cases of non-fatal suicide attempt and 294 fatal attempts. Genome-wide association

analyses were conducted using DNA from whole blood samples from subjects enrolled in MVP

using a custom Affymetrix Biobank Array. Quality control and imputation was performed as

previously described[10]. All subjects provided informed consent and the activities used to

generate the GWAS summary statistics were approved by the VA Central Institutional Review

Board and all activities were approved by the Oak Ridge National Laboratory Institutional

Review Board.

International Suicide Genetics Consortium (ISGC) suicide attempt GWAS summary statistics.

Suicide attempt summary statistics were analyzed from two sets of suicide attempt summary statistics derived from civilian populations compiled by the ISGC[9]. SNPs were included from a general population of European ancestry (SA-EUR) as 26,590 cases of suicide attempt and 492,022 control subjects. Furthermore, additional summary statistics were derived from this general population conditioned on diagnosis status for major depressive disorder (SA-MDD) to generate an additional set of suicide attempt summary statistics. Thus, while the SA-MDD summary statistics are not independent of the SA-EUR summary statistics as they are comprised of the same set of controls and cases of suicide attempt, both SA-EUR and SA-MDD summary statistics were analyzed in order to determine the overlap between these results and results from the MVP cohort. All subjects involved in the ISGC provided informed consent and the activities used to generate the GWAS summary statistics were approved by local institutional review boards as previously described[9] and by the Oak Ridge National Laboratory Institutional Review Board.

SNP to gene assignment.

SNPs were assigned to genes using two separate methods. H-MAGMA[1] was used in combination with publicly available Hi-C data from adult dorsolateral prefrontal cortex (dlPFC)[55] to improve intergenic SNP-to-gene assignment based on three-dimensional chromatin structure in this brain region. Adult prefrontal cortex Hi-C data was used as this brain region is known to be involved in executive function and impulsivity processes, which are disrupted in individuals with a history of suicide attempt[56,57]Additionally, conventional MAGMA[4] was used

as an alternate method of SNP-to-gene assignment. Thus, H-MAGMA and conventional

MAGMA were applied only as methods of assigning SNPs to genes only using SNPs at given

significance thresholds, rather than using these tools as gene-based tests on the entire set of

summary statistics.

SNPs were assigned to genes from MVP, SA-EUR, or SA-MDD summary statistics at

multiple thresholds ($p < 5e^{-8}$, $p < 1e^{-5}$, $p < 1e^{-4}$, $p < 1e^{-3}$, $p < 1e^{-2}$, and $p < 1e^{-1}$; **Supplementary**

Table 2). The union of conventional MAGMA and H-MAGMA-assigned genes (*i.e.*, all genes

assigned from either method) from MVP, SA-EUR, or SA-MDD suicide attempt summary

statistics were subsequently used as gene set inputs to GRIN at a threshold of $p < 1e^{-5}$ and were

filtered into retained and removed gene sets (**Supplementary Tables 5, 8, and 9**).

Gene set enrichment analysis.

Gene sets from MVP and ISGC summary statistics were tested for multiple enrichments

using the online ToppGene suite using ToppFun[12]. Gene set enrichments were analyzed using the

following enrichment categories: GO: Molecular Function; GO: Biological Process; GO:

Cellular Component; Human Phenotype; Pathway (all databases selected); Transcription Factor

Binding Site (all databases selected); Drug (all databases selected); Disease (all databases

selected). Enrichments were considered significant using a Benjamini-Hochberg false discovery

rate (FDR)-adjusted *p*-value threshold < 0.05.

Drug to gene target networks for putative drug repurposing and side effect evaluation.

Genes identified as contributing to suicide attempt pathophysiology from MVP and ISGC

summary statistics were used to construct drug to gene target networks from information derived

from DrugBank[58]. Drug to gene target networks were visualized in Cytoscape[59] (version 3.8.2,

Cytoscape Consortium) to identify drugs known to target genes of interest from MVP and ISGC

summary statistics using GRIN-retained genes at $p < 1e^{-5}$ (**Supplementary Table 20**). ISGC

GWAS genes were compared to genes from the MVP cohort using Venn diagrams generated

from the open source R package Vennerable (https://github.com/js229/Vennerable).

Software.

GRIN is available as an open-source, command-line R script for public use. The code,

installation instructions, and user manual can be found at https://github.com/sullivanka/GRIN.

Figures

Figure 1. Overview of GRIN – Gene set Refinement through Interacting Networks.
In stage 1, GRIN requires a network composed of gene-gene connections, preferably assembled
from multiple experimental data sources. Next, the network is explored starting from all genes in
the user's gene set using the random walk with restart algorithm, resulting in a rank-ordered list
of all genes in the network based on the frequency in which they were visited. The ordered ranks
of the user's genes are used for stage 2, where they are compared to ordered ranks obtained from
running Stage 1 on 100 random gene sets of the same size (empirical null distribution). Using the
Mann-Whitney U test, a window of the user's gene set ranks is compared to the empirical null
distribution of ranks to determine if the user's gene rankings come from the same distribution as
random genes' rankings. After using a sliding window to compare the gene ranks in this manner,
GRIN identifies a set of biologically related genes at the point at which the ranks of the user's
gene list begin to approximate the ranks of the null distribution (elbow point of the curve). Genes
prior to the sliding window at the elbow point are retained as their ranks deviate from the null
distribution, while genes beyond this point are removed.

Figure 2. GRIN retains biologically interrelated genes.

A. Workflow for assessing the capacity of GRIN to identify biologically related genes from well-defined, "gold standard" gene sets (GO, OMIM, DisGeNET) mixed with random genes. Figure made with BioRender.com. **B**. Receiver-operating characteristic (ROC) curve and precision-recall curves (PRC) for GRIN. The blue line represents the mean of GRIN performance over 100 sets of glutamatergic signaling genes (GO:0035249) intermixed with an equivalent number of random genes from the multiplex network. Gray values indicate maximum and minimum values

over 100 sets, and dotted lines indicate classification values based on random chance. **C.** Median area under ROC (AUROC) and PRC (AUPRC) values for 100 sets of random genes intermixed with a gold standard gene set for 30 distinct gold standard gene sets. **D.** Median precision, recall, and specificity values for 100 sets of a gold standard gene set intermixed with an equivalent number of random genes, repeated for 30 distinct gold standard gene sets. **E.** Violin and box plots of precision, recall, and specificity values for 100 sets of dopaminergic synaptic signaling (GO:0001963) gold standard genes intermixed with different ratios of random genes (Noise). Median precision: 0.970 (2:1), 0.767 (1:1), 0.568 (1:2), 0.360 (1:4). Median recall: 0.735 (2:1), 1.00 (1:1), 1.00 (1:2), 1.00 (1:4). Median specificity: 0.970 (2:1), 0.696 (1:1), 0.620 (1:2), 0.554 (1:4) **F.** Precision, recall, and specificity values for 100 sets of dopaminergic synaptic signaling (GO:0001963) and myelination (GO:0022010) gold standard genes mixed with a ratio of 50% noise (2:1 Gold Std:Noise) or an equivalent ratio (1:1 Gold Std:Noise) of random genes.

Figure 3. GRIN identifies biologically interrelated genes from suicide attempt summary

statistics from United States veterans.

A. Workflow for identifying biologically interrelated genes from genome-wide association study

(GWAS) summary statistics of suicide attempt from Million Veteran Program (MVP) and

International Suicide Genetics Consortium (ISGC) cohorts. Figure made with BioRender.com. **B.**

Sliding window p-values of Mann-Whitney U test for the union of H-MAGMA and conventional

MAGMA-assigned genes from MVP GWAS summary statistics using SNPs with a threshold of

$p < 1e^{-5}$. Dotted line indicates the elbow point of the curve used to determine which genes were

retained by GRIN. **C.** Gene lists of retained (blue) and removed (orange) genes from MVP

summary statistics as determined by GRIN based on H-MAGMA or conventional MAGMA

SNP-to-gene assignment.

Figure 4. GRIN retains and removes genes common to two sets of civilian suicide attempt

summary statistics.

Venn diagrams of the number of genes before GRIN (left) and retained and removed genes

following GRIN from suicide attempt of general European population (SA-EUR) and

conditioned on major depressive disorder diagnosis (SA-MDD) at $p < 1e^{-5}$. A majority of the

retained genes from SA-MDD were also retained from the SA-EUR summary statistics.

Figure 5. GRIN retains a majority of genes common among distinct suicide attempt summary statistics.
Venn diagrams of GRIN retained and removed genes from the union of MVP, SA-EUR, and SA-MDD suicide attempt summary statistics from genes assigned from SNPs at $p < 1e^{-5}$. Most genes common to multiple summary statistics were retained, as indicated by percentage of retained (orange) and removed (blue) genes in multiple sets of summary statistics. I1 = overlapping genes between MVP and SA-EUR, I2 = overlapping genes between MVP and SA-MDD, I3 = overlapping genes between SA-EUR and SA-MDD, IA = genes common to all summary statistics.

Figure 6. GRIN enhances gene set enrichment analysis.
Left: Using genes intersecting in two or more GWAS summary statistics (shaded blue region of
Venn diagram) prior to GRIN resulted in 1324 enrichments. Intersecting genes retained by GRIN
resulted in 1708 enrichments, 1259 of which were common prior to GRIN. Green: Enrichments
using intersecting genes prior to GRIN; yellow: enrichments using intersecting genes from GRIN
retained genes; purple: enrichments common to unfiltered and GRIN-retained genes. Right: Of
the 1259 enrichments common before and after applying GRIN, these enrichments were likely to
be more statistically significant (1048 enrichments, orange squares) compared to equivalent
significance (205 enrichments, open circles) or less significance (gray triangles). Diagonal line
indicates equivalent p-values before and after GRIN. Threshold for enrichment inclusion was –
$\log_{10}$(FDR-corrected p-value) > 1.30103 (FDR-corrected p-value < 0.05).

Figure 7. Neurobiological mechanisms implicated in suicide attempt pathophysiology as determined by GWAS summary statistics and GRIN.

GRIN retained genes from MVP suicide attempt GWAS (cyan), MVP and ISGC general population GWAS (orange), and MVP and both ISGC suicide attempt summary statistics (red). A number of genes related to dopaminergic signaling (*DRD2*, *PRKAR2A*, and *PDE4B*) were identified, as well as presynaptic vesicle release (*BRSK1, SGIP1*), glutamatergic synapse formation (*CELSR3*), and synaptic plasticity (*NCAM1*). Genes related to cytoskeletal reorganization (*CDC42BPB*, *MAP4*, and *MARK3*) were also implicated in suicide attempt GWAS. Genes related to chromatin reorganization (*SMARCC1*), cortical development (*TSHZ2, ZNF589*), cell lineage (*RCOR1*), and translation processes (*DALRD3*, *DHX30*, and *EIF5*) were also retained by GRIN. Together, GRIN retained genes from multiple coincident biological processes underlying suicide pathophysiology. Figure made with BioRender.com.

Figure 8. Network association of drugs and drug targets identified by suicide attempt GWAS.

Network diagram of DrugBank drugs (featured drugs green, additional drugs gray) and drug target genes from genes retained by GRIN applied to MVP and ISGC suicide attempt summary statistics at $p < 1e^{-5}$ threshold. The dopamine D2 receptor (*DRD2*), phosphodiesterase 4B (*PDE4B*), and estrogen receptor 1 (*ESR1*) are targeted by many drugs, while fostamatinib targets 8 genes implicated by suicide attempt GWAS followed by GRIN. Magenta: genes implicated in MVP and both SA-EUR and SA-MDD ISGC summary statistics; cyan: genes implicated in MVP only; orange: genes implicated in both SA-EUR and SA-MDD; brown: genes implicated in SA-EUR only; yellow: genes implicated in SA-MDD only.

References

1. Sey, N. Y. A. *et al.* A computational tool (H-MAGMA) for improved prediction of brain-disorder risk genes by incorporating brain chromatin interaction profiles. *Nat. Neurosci.* **23**, 583–593 (2020).

2. Hall, M. A. *et al.* Novel EDGE encoding method enhances ability to identify genetic interactions. *PLoS Genet.* **17**, e1009534 (2021).

3. Petersen, A., Alvarez, C., DeClaire, S. & Tintle, N. L. Assessing methods for assigning SNPs to genes in gene-based tests of association using common variants. *PLoS One* **8**, e62161 (2013).

4. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219 (2015).

5. Boyle, E. A., Li, Y. I. & Pritchard, J. K. An Expanded View of Complex Traits: From Polygenic to Omnigenic. *Cell* **169**, 1177–1186 (2017).

6. Gosak, M. *et al.* Network science of biological systems at different scales: A review. *Phys. Life Rev.* **24**, 118–135 (2018).

7. Voracek, M. & Loibl, L. M. Genetics of suicide: a systematic review of twin studies. *Wien. Klin. Wochenschr.* **119**, 463–475 (2007).

8. Erlangsen, A. *et al.* Genetics of suicide attempts in individuals with and without mental disorders: a population-based genome-wide association study. *Mol. Psychiatry* **25**, 2410–2421 (2020).

9. Mullins, N. *et al.* Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. *Biol. Psychiatry* (2021) doi:10.1016/j.biopsych.2021.05.029.

10. Kimbrel, N. A. *et al.* A genome-wide association study of suicide attempts and suicidal

ideation in U.S. military veterans. *Psychiatry Res.* **269**, 64–69 (2018).

11. Kimbrel, N. A. *et al.* A genome-wide association study of suicide attempts in the million

veterans program identifies evidence of pan-ancestry and ancestry-specific risk loci. *Mol.*

Psychiatry (2022) doi:10.1038/s41380-022-01472-3.

12. Chen, J., Bardes, E. E., Aronow, B. J. & Jegga, A. G. ToppGene Suite for gene list

enrichment analysis and candidate gene prioritization. *Nucleic Acids Res.* **37**, W305–11

(2009).

13. Wang, H., Xu, J., Lazarovici, P., Quirion, R. & Zheng, W. cAMP Response Element-

Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of

Schizophrenia. *Front. Mol. Neurosci.* **11**, 255 (2018).

14. Dvorakova, M. *et al.* SGIP1 is involved in regulation of emotionality, mood, and

nociception and modulates in vivo signalling of cannabinoid CB1 receptors. *Br. J.*

Pharmacol. **178**, 1588–1604 (2021).

15. Trevaskis, J. *et al.* Src homology 3-domain growth factor receptor-bound 2-like (endophilin)

interacting protein 1, a novel neuronal protein that regulates energy balance. *Endocrinology*

146, 3757–3764 (2005).

16. Thakar, S. *et al.* Evidence for opposing roles of Celsr3 and Vangl2 in glutamatergic synapse

formation. *Proc. Natl. Acad. Sci. U. S. A.* **114**, E610–E618 (2017).

17. Sugiura, N., Patel, R. G. & Corriveau, R. A. N-methyl-D-aspartate receptors regulate a

group of transiently expressed genes in the developing brain. *J. Biol. Chem.* **276**, 14257–

14263 (2001).

18. Takahashi, H. *et al.* MED26 regulates the transcription of snRNA genes through the

recruitment of little elongation complex. *Nat. Commun.* **6**, 5941 (2015).

19. Vukojevic, V. *et al.* Evolutionary conserved role of neural cell adhesion molecule-1 in

memory. *Transl. Psychiatry* **10**, 217 (2020).

20. Walmod, P. S., Kolkova, K., Berezin, V. & Bock, E. Zippers make signals: NCAM-

mediated molecular interactions and signal transduction. *Neurochem. Res.* **29**, 2015–2035

(2004).

21. Monaghan, C. E. *et al.* REST corepressors RCOR1 and RCOR2 and the repressor INSM1

regulate the proliferation-differentiation balance in the developing brain. *Proc. Natl. Acad.*

Sci. U. S. A. **114**, E406–E415 (2017).

22. Abrajano, J. J. *et al.* Differential deployment of REST and CoREST promotes glial subtype

specification and oligodendrocyte lineage maturation. *PLoS One* **4**, e7665 (2009).

23. Sokpor, G., Xie, Y., Rosenbusch, J. & Tuoc, T. Chromatin Remodeling BAF (SWI/SNF)

Complexes in Neural Development and Disorders. *Front. Mol. Neurosci.* **10**, 243 (2017).

24. Caubit, X., Tiveron, M.-C., Cremer, H. & Fasano, L. Expression patterns of the three

Teashirt-related genes define specific boundaries in the developing and postnatal mouse

forebrain. *J. Comp. Neurol.* **486**, 76–88 (2005).

25. Lessel, D. *et al.* De Novo Missense Mutations in DHX30 Impair Global Translation and

Cause a Neurodevelopmental Disorder. *Am. J. Hum. Genet.* **101**, 716–724 (2017).

26. Lentini, J. M., Alsaif, H. S., Faqeih, E., Alkuraya, F. S. & Fu, D. DALRD3 encodes a

protein mutated in epileptic encephalopathy that targets arginine tRNAs for 3-

methylcytosine modification. *Nat. Commun.* **11**, 2510 (2020).

27. Meltzer, H. Y. *et al.* Clozapine treatment for suicidality in schizophrenia: International

Suicide Prevention Trial (InterSePT). *Arch. Gen. Psychiatry* **60**, 82–91 (2003).

28. Carlin, D. E. *et al.* A Fast and Flexible Framework for Network-Assisted Genomic

Association. *iScience* **16**, 155–161 (2019).

29. Hristov, B. H., Chazelle, B. & Singh, M. uKIN Combines New and Prior Information with

Guided Network Propagation to Accurately Identify Disease Genes. *Cell Syst* **10**, 470–

479.e3 (2020).

30. Shim, J. E. *et al.* GWAB: a web server for the network-based boosting of human genome-

wide association data. *Nucleic Acids Res.* **45**, W154–W161 (2017).

31. Hwang, S. *et al.* HumanNet v2: Human gene networks for disease research. *Nucleic Acids*

Res. **47**, D573–D580 (2019).

32. Kim, H. *et al.* YeastNet v3: a public database of data-specific and integrated functional gene

networks for Saccharomyces cerevisiae. *Nucleic Acids Res.* **42**, D731–6 (2014).

33. Lee, T. *et al.* AraNet v2: an improved database of co-functional gene networks for the study

of Arabidopsis thaliana and 27 other nonmodel plant species. *Nucleic Acids Res.* **43**, D996–

1002 (2015).

34. Cliff, A. *et al.* A High-Performance Computing Implementation of Iterative Random Forest

for the Creation of Predictive Expression Networks. *Genes* **10**, (2019).

35. Chilton, I. *et al.* De novo heterozygous missense and loss-of-function variants in

CDC42BPB are associated with a neurodevelopmental phenotype. *Am. J. Med. Genet. A*

182, 962–973 (2020).

36. Agha, Z. *et al.* Exome sequencing identifies three novel candidate genes implicated in

intellectual disability. *PLoS One* **9**, e112687 (2014).

37. Wang, X.-X. *et al.* MRCKβ links Dasm1 to actin rearrangements to promote dendrite

development. *J. Biol. Chem.* **296**, 100730 (2021).

38. Li, L. *et al.* Protein kinases paralleling late-phase LTP formation in dorsal hippocampus in

the rat. *Neurochem. Int.* **76**, 50–58 (2014).

39. Lund, H. *et al.* MARK4 and MARK3 associate with early tau phosphorylation in

Alzheimer's disease granulovacuolar degeneration bodies. *Acta Neuropathol Commun* **2**, 22

(2014).

40. Doki, C. *et al.* Microtubule elongation along actin filaments induced by microtubule-

associated protein 4 contributes to the formation of cellular protrusions. *J. Biochem.* **168**,

295–303 (2020).

41. Neale, B. M. *et al.* Patterns and rates of exonic de novo mutations in autism spectrum

disorders. *Nature* **485**, 242–245 (2012).

42. Rehni, A. K., Singh, T. G. & Chand, P. Amisulpride-induced seizurogenic effect: a potential

role of opioid receptor-linked transduction systems. *Basic Clin. Pharmacol. Toxicol.* **108**,

310–317 (2011).

43. Rolf, M. G. *et al.* In vitro pharmacological profiling of R406 identifies molecular targets

underlying the clinical effects of fostamatinib. *Pharmacol Res Perspect* **3**, e00175 (2015).

44. Pinner, N. A., Hamilton, L. A. & Hughes, A. Roflumilast: a phosphodiesterase-4 inhibitor

for the treatment of severe chronic obstructive pulmonary disease. *Clin. Ther.* **34**, 56–66

(2012).

45. Valdeolivas, A. *et al.* Random walk with restart on multiplex and heterogeneous biological

networks. *Bioinformatics* **35**, 497–505 (2019).

46. Wang, T. *et al.* Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal

Interactions with Oncogenic Ras. *Cell* **168**, 890–903.e15 (2017).

47. Szklarczyk, D. *et al.* STRING v11: protein–protein association networks with increased

coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic*

Acids Res. **47**, D607–D613 (2018).

48. Pearl, J. R. *et al.* Genome-Scale Transcriptional Regulatory Network Models of Psychiatric

and Neurodegenerative Disorders. *Cell Syst* **8**, 122–135.e7 (2019).

49. Basu, S., Kumbier, K., Brown, J. B. & Yu, B. Iterative random forests to discover predictive

and stable high-order interactions. *Proc. Natl. Acad. Sci. U. S. A.* **115**, 1943–1948 (2018).

50. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580–

585 (2013).

51. Di Nanni, N., Bersanelli, M., Milanesi, L. & Mosca, E. Network Diffusion Promotes the

Integrative Analysis of Multiple Omics. *Front. Genet.* **11**, 106 (2020).

52. Harris, M. A. *et al.* The Gene Ontology (GO) database and informatics resource. *Nucleic*

Acids Res. **32**, D258–61 (2004).

53. Amberger, J. S., Bocchini, C. A., Schiettecatte, F., Scott, A. F. & Hamosh, A. OMIM.org:

Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and

genetic disorders. *Nucleic Acids Res.* **43**, D789–98 (2015).

54. Piñero, J. *et al.* DisGeNET: a comprehensive platform integrating information on human

disease-associated genes and variants. *Nucleic Acids Res.* **45**, D833–D839 (2017).

55. Wang, D. *et al.* Comprehensive functional genomic resource and integrative model for the

human brain. *Science* **362**, (2018).

56. Zhang, H. *et al.* Aberrant White Matter Microstructure in Depressed Patients with

Suicidality. *J. Magn. Reson. Imaging* (2021) doi:10.1002/jmri.27927.

57. Cao, J. *et al.* The Association Between Resting State Functional Connectivity and the Trait

of Impulsivity and Suicidal Ideation in Young Depressed Patients With Suicide Attempts.

Front. Psychiatry **12**, 567976 (2021).

58. Wishart, D. S. *et al.* DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Res. **36**, D901–6 (2008).

59. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular

interaction networks. *Genome Res.* **13**, 2498–2504 (2003).